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Summary  Direct  oral  anticoagulants  (DOAs)  —  inhibitors  of  thrombin  or  factor-Xa  —  are
expected  to  replace  vitamin  K  antagonists  in  most  of  their  indications.  Patients  receiving  long-
term treatment  with  DOAs  are  likely  to  be  exposed  to  elective  or  emergency  surgery  or  invasive
procedures.  Owing  to  the  present  lack  of  experience  in  such  conditions,  we  cannot  make
recommendations,  but  only  propose  perioperative  management  for  optimal  safety  regarding
the risk  of  bleeding  and  thrombosis.  DOAs  may  increase  surgical  bleeding,  they  have  no  vali-
dated antagonists,  they  cannot  be  monitored  by  simple  standardized  laboratory  assays  and  their
pharmacokinetics  vary  signiﬁcantly  between  patients.  Although  DOAs  differ  in  many  respects,
the proposals  in  the  perioperative  setting  need  not  be  speciﬁc  to  each.  For  procedures  with
low haemorrhagic  risk,  a  therapeutic  window  of  48  hours  (last  administration  24  hours  before
surgery, restart  24  hours  after)  is  proposed.  For  procedures  with  medium  or  high  haemorrhagic
risk, we  suggest  stopping  DOAs  5  days  before  surgery  to  ensure  complete  elimination  in  all
patients. Treatment  should  be  resumed  only  when  the  risk  of  bleeding  has  been  controlled.
In patients  at  high  thrombotic  risk  (e.g.  those  in  atrial  ﬁbrillation  with  a  history  of  stroke),
bridging with  heparin  (low  molecular-weight  heparin,  or  unfractionated  heparin,  if  the  former
is contraindicated)  is  proposed.  In  an  emergency,  the  procedure  should  be  postponed  for  as
long as  possible  (minimum  1—2  half-lives)  and  non-speciﬁc  antihaemorrhagic  agents,  such  as
recombinant  human  activated  factor  VIIa  or  prothrombin  complex  concentrates  should  not  be
given for  prophylactic  reversal  due  to  their  uncertain  beneﬁt-risk.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Les  anticoagulants  oraux  directs  (AOD),  anti-IIa  ou  anti-Xa,  sont  destinés  à  remplacer
les antagonistes  de  la  vitamine  K  pour  une  majorité  de  leurs  indications.  Les  patients  traités  par
ces médicaments  pourront  bénéﬁcier  d’une  chirurgie  ou  d’un  acte  invasif  programmé  ou  urgent.
L’absence  d’expérience  de  cette  situation  ne  permet  pas  d’émettre  des  recommandations,
mais seulement  des  propositions  pour  la  meilleure  gestion  possible  vis-à-vis  du  double  risque
hémorragique  et  thrombotique.  Les  AOD  sont  à  risque  hémorragique  en  cas  d’acte  invasif,  n’ont
aucun agent  de  réversion  validé,  ne  sont  pas  facilement  mesurés  par  les  tests  de  laboratoire
et leur  variabilité  individuelle  est  importante.  Bien  qu’il  existe  des  différences  entre  les  AOD,
elles n’imposent  pas  une  prise  en  charge  periopératoire  particulière  à  chacun.  Pour  les  actes
programmés  à  risque  hémorragique  faible,  il  est  proposé  de  réaliser  une  fenêtre  thérapeutique
de 48  h  encadrant  l’acte.  Pour  ceux  à  risque  hémorragique  modéré  ou  élevé,  il  est  proposé
d’interrompre  le  traitement  à  j5  pour  assurer  l’élimination  complète  du  médicament  chez  tous
les patients  et  de  ne  le  reprendre  que  lorsque  le  risque  hémorragique  est  contrôlé.  Un  relais  par
une héparine  est  justiﬁé,  si  le  risque  thrombotique  lié  à  l’indication  initiale  du  traitement  par
l’AOD est  élevé  (patients  en  ﬁbrillation  atriale  ayant  un  antécédent  cardio-embolique).  Dans
les situations  non  programmées,  l’acte  invasif  doit  être  retardé  au  maximum  (1  à  2  demi-vies
d’élimination  du  médicament  si  possible)  et  les  agents  hémostatiques  non  spéciﬁques  (facteur
VIIa recombinant,  concentrés  de  complexe  prothrombinique)  ne  doivent  pas  être  utilisés  à  titre
prophylactique.
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irect  oral  anticoagulants  (DOAs),  inhibitors  of  thrombin
r  factor-Xa  (and  potentially  inhibitors  of  factor  IXa),  are
xpected  to  replace  vitamin  K  antagonists  (VKAs)  in  the
ajority  of  their  current  indications,  such  as  the  long-
erm  treatment  and  prevention  of  venous  thromboembolism
Abbreviations: AF, Atrial ﬁbrillation; aPTT, Activated partial
hromboplastin time; DOA, Direct oral anticoagulant; GEHT, Groupe
’études sur l’hémostase et la thrombose; GIHP, Groupe d’intérêt
n hémostase périopératoire; HAS, Haute Autorité de santé; INR,
nternational normalized ratio; LMWH, Low molecular-weight hep-
rin; PCC, Prothrombin complex concentrate; PT, Prothrombin time;
FH, Unfractionated heparin; VKA, Vitamin K antagonist; VTE,
enous thromboembolism.
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VTE)  and  the  prevention  of  thromboembolic  events  in
atients  with  atrial  ﬁbrillation  (AF).  The  target  population
or  these  different  indications,  once  they  are  registered,
ould  represent  1%  of  the  population.  These  patients  will  be
reated  with  a  dose  designated  in  the  following  text  as  the
‘curative  dose’’,  summarized  in  Table  1.  This  dose  corre-
ponds  to  a  level  of  treatment  deﬁned  by  an  international
ormalized  ratio  (INR)  in  the  range  2—3  using  the  VKA  treat-
ent  that  served  as  the  comparator  in  clinical  trials.
A  signiﬁcant  proportion  of  patients  treated  with  these
rugs  will  inevitably  be  exposed  to  various  critical  situa-
ions:  accidental  or  voluntary  overdose;  spontaneous
leeding;  trauma;  or  the  need  for  scheduled  or  emer-
ency  surgery  or  invasive  procedures.  As  part  of  a  process
f  ‘‘risk  management’’  and  in  anticipation  of  marketing
uthorization,  which  may  be  granted  in  the  months  or  years
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o  come  for  the  various  DOAs  for  the  indications  listed
bove,  consultations  were  conducted  within  the  Working
roup  on  Perioperative  Haemostasis  (Groupe  d’intérêt  en
émostase  périopératoire  [GIHP])  and  the  French  Study
roup  on  Thrombosis  and  Haemostasis  (Groupe  d’études
ur  l’hémostase  et  la  thrombose  [GEHT])  concerning  the
erioperative  management  of  patients  on  these  new  treat-
ents.  These  proposals  do  not  concern  patients  receiving
OAs  for  the  prevention  of  VTE  following  major  orthopaedic
urgery,  nor  those  who  will  receive  them  for  other  indi-
ations  in  the  prevention  of  VTE  currently  covered  by  low
olecular-weight  heparins  (LMWHs),  which  may  represent  a
imple  alternative  that  is  relatively  easy  to  control  in  at-
isk  situations.  The  group  declined  to  issue  proposals  for
he  management  of  other  critical  situations  (in  particular,
cute  bleeding)  pending  the  results  of  ongoing  preclinical
nd  clinical  studies.  The  method  used  to  develop  these
roposals  was  as  follows.  A  ﬁrst  version  based  on  the
ecommendations  of  the  French  Health  Authority  (Haute
utorité  de  santé  [HAS])  for  the  perioperative  manage-
ent  of  patients  treated  with  VKAs  [1]  (www.has-sante.fr)
as  adapted  for  DOAs  using  the  published  pharmacological
ata  collected  mainly  during  the  phase  I  and  II  studies  of
hese  drugs.  Some  of  these  are  included  in  the  ‘‘Rationale’’
ection  below.  This  text  was  then  submitted  for  several
ounds  of  critical  analysis  by  the  members  of  GIHP  and  the
harmacology  group  of  the  GEHT,  until  a  consensus  was
eached.
ationale
reatment  with  a  curative  dose  of  a  DOA  is  associated  with
 risk  of  bleeding  DOAs  were  developed  to  be  used  without
aboratory  controls  and  without  the  need  for  dose  adjust-
ent,  which  could  give  them  an  important  advantage  in
erms  of  convenience  over  VKAs.  However,  the  incidence
f  spontaneous  bleeding  described  as  ‘‘major’’  during  the
rials  was  still  signiﬁcant  compared  with  VKAs  [2—5]  and
emains,  even  at  low  doses,  higher  than  that  of  placebo
6].  Although  the  therapeutic  range  is  wider  and  the  sta-
ility  of  the  anticoagulant  effect  better  than  that  of  VKAs,
he  risk  of  bleeding  at  the  recommended  dose  should  be
aken  into  consideration  in  the  event  of  surgery  or  invasive
rocedures.
irect oral anticoagulants (DOAs) have no
ffective antidote
nlike  VKAs,  which  can  be  antagonized  by  vitamin  K  and
y  prothrombin  complex  concentrates  (PCCs)  that  provide
he  vitamin  K  dependent  factors  II,  VII,  IX  and  X,  the
ew  DOAs  have  no  speciﬁc  antidote.  An  antagonist  that
cts  as  a  decoy  with  regard  to  factor-Xa  (recombinant
on-carboxylated  factor-Xa  without  clotting  activity)  [7]  is
eing  tested  ex  vivo  [8].  This  strategy  is  not  applicable  to
nhibitors  of  thrombin,  as  thrombin  is  not  -carboxylated,
ut  other  approaches  can  be  imagined.  For  example,  a
umanized  monoclonal  antibody  speciﬁc  to  dabigatran  was
ecently  proposed  as  a  speciﬁc  antagonist  [9].  Even  if  their
linical  efﬁcacy  can  be  demonstrated,  these  agents  will
ot  be  marketed  for  several  years.  Thus,  the  currently
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vailable  non-speciﬁc  reversing  agents  potentially  include:
on-activated  (Kanokad®,  Octaplex®)  or  activated  (FEIBA®)
CCs  and  activated  recombinant  human  factor  VIIa  (r-fVIIa,
ovoSeven®).  These  were  proposed  on  the  basis  of  an
xtrapolation  of  experimental  [10—14]  and  clinical  [15]  data
n  the  reversal  of  fondaparinux  or  idraparinux  (parenteral
ntithrombin-dependent  inhibitors  of  factor-Xa)  or  melaga-
ran  (the  ﬁrst  direct  oral  thrombin  inhibitor,  now  withdrawn
rom  the  market).  However,  these  data  are  fragmentary.
he  effectiveness  of  these  drugs  is  controversial  and  their
afety  in  terms  of  thrombotic  risk  in  the  target  population
as  not  been  established.  The  arterial  risk  of  r-fVIIa  [16]
nd,  potentially,  that  of  the  other  antagonists  that  have  not
een  studied  as  thoroughly,  is  a  concern  among  vascular  and
ften  elderly  patients.  A  venous  risk  has  not  been  shown
n  clinical  trials,  but  these  excluded  patients  with  a  his-
ory  of  VTE,  for  whom  a  DOA  could  be  prescribed.  Finally,
he  modalities  of  these  treatments  in  this  indication  (dose,
requency  of  administration,  etc.)  are  not  known.  In  prac-
ice,  the  safety  of  a  scheduled  surgical  or  invasive  procedure
s  based  primarily  on  the  natural  clearance  of  the  antico-
gulant  after  preoperative  suspension  of  treatment.  PCCs,
-FVIIa  and  possibly,  in  the  case  of  failure  of  these,  plasma
uriﬁcation  techniques  (dialysis  or  haemoﬁltration  for  DOAs
uch  as  dabigatran  that  bind  only  weakly  to  plasma  proteins
nd  plasmapheresis  for  other  DOAs)  could,  in  exceptional
ircumstances,  provide  an  emergency  solution  when  faced
ith  refractory  severe  bleeding.
he interindividual pharmacokinetic
ariability  of direct oral anticoagulants (DOAs)
s large
he  four  drugs  that  are  most  advanced  in  their  clini-
al  development  and  regulatory  proceedings  (dabigatran,
ivaroxaban,  apixaban  and  edoxaban)  differ  in  their  rate
nd  extent  of  digestive  adsorption  and  in  the  mechanisms
nd  rate  of  elimination,  predominantly  renal  or  hepatobil-
ary.  The  values  reported  in  Table  1  for  patients  are  similar
o  those  reported  for  healthy  volunteers  [17]. As  the  blood
oncentration  of  the  drug  decreases  exponentially  beyond
max,  it  is  expected  that  at  the  suspension  of  treatment,
bout  10%  of  the  value  of  Cmax (theoretically  12.5%)  is
eached  after  3  half-lives.  It  is  interesting  to  recall  that
n  a  surgical  context,  the  risk  of  bleeding  appears  to  be
ore  closely  related  to  the  value  of  Cmin than  to  that  of
max [18]. However,  the  absorption,  distribution,  metabolism
nd  elimination  of  these  drugs  are  governed  by  many  vari-
bles:  liver  and/or  renal  function,  sex,  weight,  age,  genetic
olymorphisms  of  enzyme  or  efﬂux  systems,  drug-drug  inter-
erence,  etc.  It  follows  that  for  a  given  patient,  the  residual
oncentration  at  a  given  time  after  halting  treatment  can-
ot  be  accurately  calculated  from  the  average  values  of  the
harmacokinetics  in  the  target  population.
Thus,  at  steady  state  (i.e.  3  to  5  days  on  average  after
tarting  treatment),  the  Cmax and  Cmin of  dabigatran  at  a
ose  of  150  mg  twice  daily  had  coefﬁcients  of  variation  of
bout  70—80%  in  the  BISTRO  I  study  [19]  and  a  high  disper-
ion  of  Cmin in  the  PETRO  study  [20]. Similarly,  the  Cmin and
max following  20  mg  rivaroxaban  once  daily  in  phase  II  trials
n  hip  replacement  surgery  [21]  or  30/60  mg  edoxaban  in
t
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atients  with  AF  [18], were  subject  to  signiﬁcant  variability.
inally,  in  daily  clinical  practice,  for  the  doses  approved  in
rthopaedic  surgery,  the  equilibrium  Cmax measured  beyond
he  ﬁfth  day  is  assigned  coefﬁcients  of  variation  of  the  order
f  81%  and  67%  for  dabigatran  and  rivaroxaban,  respectively
22].
irect oral anticoagulants (DOAs) cannot be
onitored by a simple standardized
aboratory  test, accessible to all
on-specialized laboratories
t  pharmacological  doses,  these  drugs  have  an  effect  on  rou-
ine  coagulation  assays  (prothrombin  time  [PT],  activated
artial  thromboplastin  time  [aPTT]).  The  sensitivity  of  these
ssays  varies  with  the  reagents  used  [13,23]. This  is  partic-
larly  the  case  for  PT,  whether  its  results  are  expressed  as
 PT  ratio  or  an  INR.  The  INR  performed  in  routine  practice
s  standardized  to  measure  the  effect  of  VKAs,  but  this  is
ot  so  for  DOAs  [24]. Furthermore,  for  a  given  concentra-
ion,  the  results  for  PT  and  aPTT  vary  between  individuals
s  a  function  of  factors  that  have  not  yet  been  identiﬁed
G.  Freyburger,  personal  communication).  It  is  important  to
emember  that  the  therapeutic  ranges  and  safety  thresholds
f  INR  validated  for  VKAs  do  not  apply  to  the  new  anti-
oagulants.  For  example,  an  INR  of  1.5  corresponds  to  a
ow  risk  of  surgical  bleeding  for  a  patient  who  has  stopped
KA  treatment.  The  same  INR  value  corresponds,  in  vitro,  to
lasma  overloaded  with  0.2  g/mL  of  rivaroxaban  [23,24],
 concentration  in  the  range  of  the  Cmax observed  after
ral  administration  of  20  mg.  To  avoid  any  confusion,  the
xpression  of  results  as  an  INR,  even  standardized,  should
ot  be  done.  To  interpret  the  results  of  a  coagulation  test
rescribed  to  monitor  a  patient’s  haemostasis  (e.g.  in  the
ase  of  postoperative  bleeding),  the  interference  of  DOAs
ith  routine  coagulation  assays  should  be  known.  This  has
een  reported  in  the  course  of  preventive  treatment  with
abigatran  and  rivaroxaban  in  major  orthopaedic  surgery
22],  but  is  not  published  for  patients  treated  with  a  cura-
ive  dose.  Based  on  phase  II  trials,  INR  values  varying  widely
round  1.5  (expression  as  an  INR  unsuitable  for  reasons  indi-
ated  above)  and  aPTT  patient/control  ratios  between  1.5
nd  2  are  expected  at  Cmax at  equilibrium.  This  interference
hould  disappear  after  2  half-lives,  but  as  indicated  below,
he  pharmacokinetic  variability  is  large  and  the  interference
ay  persist  beyond  24  hours.  Finally,  aPTT  prolongation  is
haracterized  by  a  very  pronounced  plateau  effect  at  high
OA  concentrations  in  vitro,  making  this  test  unsuitable  for
he  detection  of  overdoses.
Dedicated  assays  derived  from  thrombin  clotting  time
r  ecarin  clotting  time  or  factor-Xa  inhibitor  chromogenic
esting  will  soon  be  available  to  measure  DOA  plasma  con-
entrations  using  appropriate  calibration.  It  is  not  clear,
owever,  whether  they  will  be  available  in  the  near  future  to
on-specialized  laboratories,  which  is  a  prerequisite  if  they
re  to  be  used  in  contexts  of  relative  urgency.
The  security  objective  that  must  be  reached  for  DOAs  in
he  context  of  surgery  or  an  invasive  procedure  has  not  yet
een  deﬁned.
The  interpretation  and  use  of  laboratory  test  results,
hatever  they  may  be,  implies  that  safety  thresholds  exist.
oral  anticoagulants  673
Figure 1. Example of a protocol for creating a direct oral anti-
coagulant therapeutic window for surgery or an invasive procedure
with a low risk of bleeding (A) or a moderate or high risk of bleeding
(B). In the case of bridging with a heparin (situation B), no overlap
of the two anticoagulants is allowed, either preoperatively or post-
o
h
b
o
t
i
p
r
I
w
t
m
i
i
t
o
m
t
s
D
D
8
e
p
4
e
oSurgery  and  invasive  procedures  in  patients  treated  by  new  
As  yet,  no  preclinical  or  clinical  data  allow  us  to  deﬁne  a  min-
imum  plasma  concentration  below  which  the  risk  of  bleeding
during  surgery  is  not  different  from  that  of  a  non-treated
subject.
Proposals
As  the  future  indications  for  treatment  with  DOAs  are  the
same  as  those  for  VKAs  and  in  the  absence  of  perioper-
ative  experience  with  these  new  drugs,  an  adaptation  of
the  recommendations  published  by  the  HAS  for  VKAs  ([1]
www.hassante.fr) is  proposed.  To  avoid  introducing  addi-
tional  complexity,  the  authors  consider  that  the  aspects  that
DOAs  have  in  common  are  more  important  than  those  that
differentiate  them,  as  for  LMWHs,  which,  although  different
from  one  another,  are  in  practice  regarded  as  a  homoge-
neous  class.  Therefore,  in  the  absence  of  information  to
the  contrary,  no  distinction  will  be  made  in  the  proposals
in  terms  of  the  drug  used.  In  the  future,  the  introduction  of
new  DOAs,  with  pharmacokinetic  proﬁles  that  may  be  signif-
icantly  different  from  those  presented  in  Table  1,  could  lead
to  drug-speciﬁc  attitudes.  The  proposals  differ  depending  on
whether  the  situation  is  scheduled  or  is  one  of  emergency.
For  scheduled  situations,  they  rank  the  surgical  or  invasive
procedures  depending  on  the  potential  for  bleeding  and  the
thrombotic  risk  to  which  the  patient  would  be  exposed  on
interruption  of  anticoagulant  therapy  in  the  perioperative
period.
Scheduled surgery or invasive procedures
with low risk of bleeding
These  are  the  procedures  for  which  bleeding,  if  it  occurs,
will  be  of  low  abundance,  non-critical  in  its  location
and/or  easily  controlled  by  simple  mechanical  haemostasis.
These  elements  must  be  assessed  according  to  the  nature
of  the  procedure,  the  type  of  anaesthesia,  postoperative
monitoring  opportunities  and  patient-speciﬁc  conditions,
especially  concomitant  medications  that  might  interfere
with  haemostasis  [25]. It  should  be  noted  that  the  estimates
of  risk  on  which  these  recommendations  are  based  are  doc-
umented  only  for  treatment  with  VKAs,  with  a  low  level
of  evidence  (experts’  opinion)  and  remain  controversial  for
certain  procedures.  In  the  absence  of  a  validated  antago-
nist,  the  major  component  of  risk  assessment  is  the  ability
to  mechanically  control  a  possible  bleed.  In  these  patients,
provided  that  a  laboratory  assessment  of  the  absence  of
overdose  is  performed  by  measuring  the  INR,  VKA  treatment
would  not  be  interrupted.  Owing  to  the  lack  of  a  validated
antagonist,  it  is  proposed  to  produce  a  short  therapeutic
window  as  follows:  last  administration  of  the  DOA  24  hours
before  the  procedure  and  restart  24  hours  after  it  (Fig.  1A).
Associated  aspirin  monotherapy  does  not  change  this  highly
conservative  proposition.
Scheduled surgery or invasive procedures at
moderate or high risk of bleedingThis  includes  all  procedures  for  which  the  probability  of  clin-
ically  signiﬁcant  bleeding  cannot  be  excluded  or,  a  fortiori,
any  surgery  that  is  usually  haemorrhagic  or  for  which  the  risk
V
i
e
iperatively. Direct oral anticoagulant (DOA); low molecular-weight
eparin (LMWH); unfractionated heparin (UFH); venous thromboem-
olism (VTE).
f  bleeding  would  be  unacceptable.  In  these  patients,  VKA
reatment  would  be  stopped  early  enough  to  perform  the
ntervention  in  conditions  of  haemostatic  safety  based  on
reoperative  monitoring  of  the  INR.  VKA  treatment  would  be
esumed  postoperatively  after  checking  the  risk  of  bleeding.
f  necessary,  the  thrombotic  risk  during  the  VKA  therapeutic
indow  would  be  prevented  by  heparin  (LMWH  or  unfrac-
ionated  heparin  [UFH]).  In  patients  receiving  a  DOA,  the
anagement  of  thrombotic  risk  does  not  differ  from  that
n  patients  who  could  have  been  on  a  VKA  for  the  same
ndication.  It  is  therefore  necessary  to  set  the  duration  of
he  therapeutic  window  and  then  to  discuss  how  the  risk
f  thrombosis,  for  which  the  long-term  anticoagulant  treat-
ent  with  a  DOA  was  prescribed,  can  be  prevented  during
his  interruption.  An  example  of  the  proposed  protocol  is
hown  in  Fig.  1B.
uration  of  the  therapeutic  window
iscontinuation  of  treatment  on  day-5  (last  administration
:00  PM)  for  a  procedure  scheduled  on  day  0,  is  proposed
mpirically.  Indeed,  although  using  the  database  of  average
harmacokinetic  variables,  it  may  be  possible  to  propose
8  hours  (∼3  mean  half-lives)  as  the  duration  of  preop-
rative  suspension  of  treatment  suitable  for  the  majority
f  patients,  haemostatic  safety  is  not  guaranteed  for  all.
arious  covariates  (liver  and/or  renal  function,  drug-drug
nteractions,  genetic  polymorphisms,  etc.)  may  signiﬁcantly
xtend  the  elimination  half-life  of  the  drug.  Until  there
s  proof  to  the  contrary,  in  the  absence  of  a  validated
6a
f
b
m
b
T
f
s
d
a
r
o
a
r
t
r
e
f
f
p
M
t
D
b
i
P
T
p
e
p
c
w
u
f
c
r
t
o
i
b
1
r
p
W
s
a
(
a
s
a
P
P
o
i
r
t
a
P
a
I
a
o
c
a
r
k
w
s
a
E
T
r
1
s
o
i
p
t
c
F
I
a
r
u
f
A
t
c
[
C
T
i
t
p
t
i
p
r
t
a
t
i
a
t74  
ntagonist,  the  residual  concentration  must  be  close  to  0
or  safety  of  procedures  with  a  high  risk  of  bleeding.  Throm-
in  time  and  anti-Xa  assays  conﬁgured  and  calibrated  for
easuring  heparins  are  very  sensitive  to  the  effect  of  throm-
in  and  direct  oral  factor-Xa  inhibitors  [13,23],  respectively.
herefore,  a  thrombin  time  identical  to  the  control  or
actor-Xa  inhibitor  activity  less  than  0.1  U/mL  can,  if  neces-
ary,  be  used  to  afﬁrm  that  this  goal  has  been  achieved.
Restarting  postoperative  DOA  treatment  at  a  curative
ose  is  determined  by  the  possibility  of  oral  administration
nd  the  risk  of  postoperative  bleeding,  either  surgical  or
elated  to  the  anaesthetic  technique.  For  the  latter,  the  rec-
mmendations  of  the  European  Society  of  Anaesthesiology,
pplicable  to  the  prophylaxis  of  VTE  after  surgery,  have  been
ecently  updated  [26]. The  absence  of  an  antagonist  requires
hat  the  resumption  of  a  curative  dose  is  delayed  until  this
isk  has  been  controlled  with  certainty.  The  anticoagulant
ffect  of  DOAs  is  obtained  within  a  few  hours,  unlike  that
or  VKAs  (Table  1).  The  recovery  time  is  highly  variable  (a
ew  hours  to  several  days)  depending  on  the  nature  of  the
rocedure.
anagement  of  thrombotic  risk  during  the
herapeutic  window
uring  the  therapeutic  window,  bridging  with  a  heparin  can
e  put  in  place  or  not,  depending  on  the  importance  of  the
ndividual  risk  of  thrombosis.
atients  at  high  risk  of  thrombosis
hese  are  patients  with  a  recent  history  (<  3  months)  of
roximal  venous  thrombosis  with  or  without  pulmonary
mbolism,  patients  with  recurrent  idiopathic  VTE  and
atients  with  AF  at  high  risk  because  of  a  history  of
ardioembolic  disease.  For  these  patients,  a  therapeutic
indow  of  several  days  is  risky.  Bridging  is  imperative,
sing  LMWH  (or  UFH  if  there  is  a  contraindication  to  the
ormer),  administered  at  the  curative  dose  as  two  sub-
utaneous  injections  per  day,  according  to  the  modalities
ecommended  for  VKA  bridging  [1].
Treatment  with  heparin  should  be  initiated  12  hours  after
he  last  dose  of  the  DOA,  if  it  is  administered  twice  a  day
r  24  hours  after  the  last  dose  of  the  DOA,  if  it  is  admin-
stered  once  a  day.  The  treatment  with  heparin  should
e  discontinued  before  surgery  (last  administration  24  and
2  hours  before  surgery  for  LMWH  and  subcutaneous  UFH,
espectively)  and  restarted  after  surgery  when  the  risk  of
ostoperative  bleeding  is  considered  to  be  under  control.
hen  the  DOA  can  be  resumed  safely,  the  ﬁrst  oral  dose
hould  be  administered  12  hours  after  the  last  subcutaneous
dministration  of  LMWH.  Owing  to  the  rapid  action  of  DOAs
Table  1),  they  should  never  be  given  together  with  hep-
rin,  whatever  the  dose  of  the  latter.  Unlike  for  VKAs,  there
hould  be  no  overlap  between  treatment  with  heparin  and
 DOA,  regardless  of  the  dose.
atients  at  moderate  risk  of  thrombosis
reoperative  bridging  with  heparin  may  be  considered  as
ptional.  However,  the  postoperative  thrombotic  risk  may  be
ncreased  by  inﬂammation.  If  the  DOA  treatment  cannot  be
esumed  rapidly  (e.g.  due  to  the  impossibility  of  administra-
ion  by  an  oral  route),  a  curative  dose  of  heparin  is  advised,
s  soon  as  the  bleeding  risk  is  controlled.
t
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revention of venous thromboembolism (VTE)
fter surgery
f  the  resumption  of  postoperative  anticoagulant  therapy  at
 curative  dose  (heparin  or  DOA)  is  delayed  and  prophylaxis
f  VTE  after  surgery  is  indicated,  it  should  be  performed
onventionally  using  a  heparin  or  by  mechanical  means  if
ll  types  of  anticoagulant  are  contraindicated.  It  should  be
ecalled  that,  to  date,  none  of  the  DOAs  has  received  mar-
eting  approval  as  a  prophylactic  for  postoperative  VTE,
ith  the  exception  of  major  orthopaedic  surgery.  As  empha-
ized  above,  no  overlap  of  heparin  therapy  and  a  DOA  is
llowed.
mergency surgery or invasive procedures
he  time  of  last  dose  must  be  known.  If  surgery  is  haemor-
hagic,  it  should  be  delayed  for  as  long  as  possible  (at  least
 or  2  elimination  half-lives  of  the  drug  or  based  on  a  sen-
itive  laboratory  assay  [a  normal  thrombin  time  or  absence
f  detectable  activity  for  factor-Xa  inhibitor  for  thrombin
nhibitor  and  factor-Xa  inhibitor  drugs,  respectively]);  this  is
rovided  that  the  delay  does  not  imply  a  loss  of  chance  for
he  patient.  At  present,  no  other  overall  recommendation
an  be  made.
The  beneﬁt—risk  of  non-speciﬁc  antagonists  (PCCs,  r-
VIIa,  etc.)  should  be  evaluated  on  an  individual  basis.
n  the  absence  of  bleeding,  they  cannot  be  recommended
s  preventive  measures  and  are  instead  proposed  for  the
escue  from  bleeding  that  cannot  be  controlled  by  the
sual  means.  To  date,  there  is  no  published  evidence  in
avour  of  r-FVIIa  rather  than  a PCC  (activated  or  not).
 plasma  clearance  technique  would  probably  be  effec-
ive,  but  difﬁcult  to  implement  in  this  context.  In  all
ases,  neuraxial  anaesthesia  is  strictly  contraindicated
26].
onclusion
he  introduction  of  DOA  treatment  for  patients  receiv-
ng  long-term  anticoagulation  therapy  at  a  level  equivalent
o  that  of  VKA  treatment  poses  the  problem  of  the
erioperative  management  of  these  patients.  However,
his  has  never  been  well  evaluated  by  preclinical  stud-
es  or  clinical  trials  in  an  unselected  population.  The
roposals  put  forward  here  highlight  the  need  for  secu-
ity  regarding  the  risk  of  bleeding,  without  compromising
he  protection  expected  against  the  thrombotic  risk;  they
re  likely  to  evolve  and  become  more  clearly  deﬁned  in
he  course  of  the  practitioner’s  individual  experience.  It
s  important  that  clinical  cases  are  published  and  any
dverse  events  reported  to  the  pharmacovigilance  authori-
ies.
Since  the  submission  of  this  paper,  the  results  of  the  Aris-
otle  trial  comparing  apixaban  with  warfarin  in  patients  with
trial  ﬁbrillation  have  been  published  [27]; the  results  were
romising  but  do  not  fundamentally  change  the  present  pro-
osals.
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